4, 5 So it provided some, but not all, of the essential fatty acids needed for patients dependent on PN to prevent fatty acid deficiency. 3 It consisted of 77% omega-6 fatty acids 2, 3 but lacked ALA, which is an essential fatty acid. The first product available in the United States was released in 1961 and was made from safflower oil. 1 Vitamin E is also added to help reduce the oxidative stress of the emulsion components, as well as the oxidative stress on patients. In addition, alpha linolenic acid (ALA), which is used as a stabilizing agent for the emulsion, makes up a small percentage of the emulsion. The emulsion is a mixture of 3 fatty acids: omega-6, -3, and -9. Once the emulsion was developed, it was heralded as a breakthrough for patients who required long-term PN and who previously were limited to dextrose and amino acids for sources of their calories. 2 Patients' conditions could be complicated by excessive dextrose intake, which can cause hyperglycemia increased carbon dioxide production hepatic steatosis and phagocyte destruction. The deficiencies can present as cholestasis, steatosis, alopecia, dermatitis, and thrombocytopenia. 1, 2 Before the development of IVFE, patients would develop essential fatty acid deficiencies. 239000003995 emulsifying agent Substances 0.Intravenous fat emulsion (IVFE) is a mixture of long-chain fatty acids originally formulated to provide essential fatty acids for patients on parenteral nutrition (PN) and a dense source of calories to help reduce the volume required for PN.238000001990 intravenous administration Methods 0.000 title claims description 12.238000001802 infusion Methods 0.000 title claims description 12.239000002960 lipid emulsion Substances 0.000 title claims abstract description 79.Status Expired legal-status Critical Current Links Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Family has litigation Priority to US4116587A priority Critical Priority to US41165 priority Application filed by Baxter International Inc filed Critical Baxter International Inc Publication of EP0313617A1 publication Critical patent/EP0313617A1/en Publication of EP0313617A4 publication Critical patent/EP0313617A4/en Application granted granted Critical Publication of EP0313617B1 publication Critical patent/EP0313617B1/en First worldwide family litigation filed litigation Critical (B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License. Original Assignee Baxter International Inc Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) ( en Inventor Richard Cotter Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Expired Application number EP19880904135 Other languages German ( de) Google Patents Lipid emulsion and method for intravenous infusionĭownload PDF Info Publication number EP0313617B1 EP0313617B1 EP19880904135 EP88904135A EP0313617B1 EP 0313617 B1 EP0313617 B1 EP 0313617B1 EP 19880904135 EP19880904135 EP 19880904135 EP 88904135 A EP88904135 A EP 88904135A EP 0313617 B1 EP0313617 B1 EP 0313617B1 Authority EP European Patent Office Prior art keywords lipid emulsion oil lipid emulsifier emulsion Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. Google Patents EP0313617B1 - Lipid emulsion and method for intravenous infusion ![]() EP0313617B1 - Lipid emulsion and method for intravenous infusion
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |